Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS
Contenuto archiviato il 2024-05-29

E2F3 - a potential clinical marker for prostate cancer

Obiettivo

Prostate cancer is now the leading cause of cancer related deaths in most European countries. However, knowledge of the underlying mechanisms is still scarce. The overall aim of this project is to identify new oncogenes involved in prostate cancer and assess their potential as clinical markers. The focus will be the E2F3 transcription factor that has an established role in cell cycle progression and has recently been proposed as a candidate oncogene for bladder cancer. Initial studies indicate that 70% of prostate cancers over-express E2F3.

We will combine tissue microarray (TMA) staining data from 1200 prostate cancer patients with clinical data, and statistically analyse the correlation. We will also test the hypothesis that down regulation of pBR is needed for upregulation of E2F3 to have an impact, by studies of the pBR levels in parallel with the E2F3 analysis on the TMAs. We will determine whether the upregulation is associated with increased copy number of the gene by flourescence in situ hybridisation ( FISH) onto TMAs and, finally, the biological role of E2F3 in the development of prostate cancer will be investigated by siRNA technology in prostate cancer cell lines that over-express E2F3.

Campo scientifico (EuroSciVoc)

Argomento(i)

Invito a presentare proposte

FP6-2002-MOBILITY-5
Vedi altri progetti per questo bando

Meccanismo di finanziamento

EIF - Marie Curie actions-Intra-European Fellowships

Coordinatore

INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL
Contributo UE
Nessun dato
Costo totale
Nessun dato